Reshaping Tumour Immunity with Precision and Purpose.
Eidolon’s New Generation of Immunotherapy
Eidolon’s technology leverages engineered microbial proteins to convert cold immune-suppressive tumours into hot immune-responsive tumours whilst minimising harmful, chronic inflammation.
Eliminate Cancer Cells Precisely and Rapidly
Maximise
Anti-Tumour Immunity
Minimise
Chronic Inflammation
Meet the team
A team of scientists and innovators dedicated to transforming immunotherapy, based at the Institute of Cancer Research and Imperial College London.
Read our latest news
07/08/2025